How Rhapsido’s symptomatic dermographism approval expands Novartis immunology strategy
Novartis’ Rhapsido won the first FDA label for symptomatic dermographism after a 29.3% complete response in Phase 3 RemIND.
Pharma & Biotech
Features & Analysis
Rhapsido doubles complete hive response rate as Novartis secures new FDA indication
FDA approves Novartis Rhapsido as the first treatment specifically for symptomatic dermographism after positive Phase III RemIND results.
Features & Analysis
Barzolvolimab can eliminate hives and itch for about half of patients. What does Celldex need to prove before launch?
Celldex Therapeutics has delivered positive results from both Phase 3 EMBARQ studies of barzolvolimab in chronic spontaneous urticaria, with roughly 42% to 46% of treated patients completely free of hives and itch by Week 12 and response rates deepening through Week 24. The clinical programme also produced substantial activity after omalizumab failure and against angioedema,
Pharma & Biotech
Remibrutinib clears pivotal multiple sclerosis tests with no liver safety signal as Novartis eyes approvals
Remibrutinib wins two Phase III multiple sclerosis trials as Novartis prepares global filings. See what the results mean for the BTK race.
Pharma & Biotech
Novartis remibrutinib beats teriflunomide in two Phase 3 multiple sclerosis trials
Novartis says oral BTK inhibitor remibrutinib significantly reduced relapse rates and MRI lesions versus teriflunomide in both Phase 3 REMODEL trials, with no liver safety signal and global regulatory filings now planned.